methyl 4-[(4-methoxyphenyl)(piperidin-4-ylidene)methyl]phenoxide | 133365-39-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-[(4-methoxyphenyl)(piperidin-4-ylidene)methyl]phenoxide
• 英文别名: 4-[bis(4-methoxyphenyl)methylene]piperidine；4-[bis(4-methoxyphenyl)methylidene]piperidine
• CAS: 133365-39-6
• 化学式: C₂₀H₂₃NO₂
• 分子量: 309.408
• InChiKey: DXQDQSLQGQJAMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-[(4-methoxyphenyl)(piperidin-4-ylidene)methyl]phenoxide 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 4-[bis(4-methoxyphenyl)methyl]-piperidine
  参考文献：
  名称：

  Characterization of Tunable Piperidine and Piperazine Carbamates as Inhibitors of Endocannabinoid Hydrolases

  摘要：

  Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) are two enzymes froth the serine hydrolase superfamily that degrade the endocannabinoids 2-arachidonoylglycerol and anandamide, respectively. We have recently discovered that MAGL and FAAH arc both inhibited by carbamates bearing an N-piperidine/piperazine group. Piperidine/piperazine carbamates show excellent in vivo activity, raising brain endocannabinoid levels and producing CBI-dependent behavioral effects in mice, suggesting that they represent a promising class of inhibitors for studying the endogenous functions of MAGL and FAAH. Herein, we disclose a full account of the syntheses, structure-activity relationships, and inhibitory activities of piperidine/piperazine carbamates against members of the serine hydrolase family. These scaffolds can be tuned for MAGL-selective or dual MAGL-FAAH inhibition by the attachment of an appropriately substituted bisarylcarbinol or aryloxybenzyl moiety, respectively, on the piperidine/piperazine ring. Modifications to the piperidine/piperazine ring ablated inhibitory activity, suggesting a strict requirement for a six-membered ring to maintain potency.

  DOI：

  10.1021/jm9016976
• 作为产物：
  描述：

  N-乙氧羰基-4-哌啶酮 在 水 、 四氯化钛 、 potassium hydroxide 、 锌 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 18.0h， 生成 methyl 4-[(4-methoxyphenyl)(piperidin-4-ylidene)methyl]phenoxide
  参考文献：
  名称：

  对称的4,4'-（哌啶-4-亚甲基亚甲基）双酚衍生物作为新型可调雌激素受体（ER）调节剂

  摘要：

  我们设计并合成了4,4'-（哌啶-4-亚甲基亚甲基）双酚衍生物作为新型可调雌激素受体（ER）调节剂。在哌啶环的氮原子上引入疏水取代基可增强ERα的结合亲和力。另外，与哌啶环氮原子相邻的四个甲基的引入显着增强了ERα结合亲和力。N-乙酰基-2,2,6,6-四甲基哌啶衍生物3b在大鼠肝脏S9组分中显示出较高的ERα结合亲和力，较高的MCF-7细胞增殖诱导活性和较高的代谢稳定性。

  DOI：

  10.1016/j.bmc.2016.01.035

文献信息

• Heterocyclic compound having serotonine 2-receptor antagonistic activity
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US05232924A1

  公开（公告）日：1993-08-03

  A heterocyclic compound represented by formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl group, an aryl group which may be substituted with one or more substituents selected from the group consisting of a halogen atom, an alkoxy group, an alkyl group and a trihalogenomethyl group; .lambda. represents 0 or 1; ring A represents a 6 membered heterocyclic ring containing the nitrogen atom shared with the triazine ring and which may contain one or more double bonds; Y represents a substituted or unsubstituted alkylene group having 1 to 15 carbon atoms; and Q represents a group represented by formula (II): ##STR2## wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are represented by substituents disclosed herein; or salt thereof, and intermediates therefor are described. The compound of formula (I) or salt thereof exhibit selective serotonin 2-receptor antagonistic activity and are useful for the prevention or treatment of circulatory diseases, e.g., ischemic heart diseases, cerebral vessel disturbances, and peripheral circulation disturbances.

  一种由式(I)表示的杂环化合物：##STR1##其中R1表示氢原子、烷基组、可能被一个或多个选自卤素原子、烷氧基组、烷基组和三卤甲基组的取代基取代的芳基组；λ表示0或1；环A表示含有与三嗪环共用氮原子的6元杂环环，该环可能含有一个或多个双键；Y表示具有1至15个碳原子的取代或未取代的亚烷基组；Q表示由式(II)表示的组：##STR2##其中R2、R3、R4和R5由本文披露的取代基表示；或其盐，以及其中间体。式(I)的化合物或其盐表现出对血清素2受体的选择性拮抗活性，并可用于预防或治疗循环系统疾病，例如缺血性心脏病、脑血管障碍和外周循环障碍。
• Synthesis of novel 4-(diarylmethylene)piperidines
  作者：Zong-ying Liu、Zhuo-rong Li、Jian-dong Jiang、D. W. Boykin

  DOI：10.1515/hc.2009.15.6.401

  日期：2009.1

  An efficient sequence to the seven novel 4-(diarylmethylene)piperidines starting from the commercially available l-acetylpiperidme-4-carboxylic acid is reported.

  七种新型 4-(二芳基亚甲基) 哌啶的有效序列从市售的 l-乙酰哌啶-4-羧酸开始被报道。
• Syntheses of 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives
  作者：Yoshifumi Watanabe、Hiroyuki Usui、Shozo Kobayashi、Hirotaka Yoshiwara、Toshiro Shibano、Tsuyoshi Tanaka、Yoshiyuki Morishima、Megumi Yasuoka、Munefumi Kanao

  DOI：10.1021/jm00079a026

  日期：1992.1

  2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives with a 4-[bis(4-fluoro-phenyl)methylene]piperidine or 4-(4-fluorobenzoyl)piperidine group has been prepared and tested for 5-HT2 and alpha 1 receptor antagonist activity. Among the compounds prepared, 2-[2-[4-[bis(4-fluorophenyl)methylene]-piperidin-1-yl]ethyl]- 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one (7b) had the most

  一系列带有4- [双（4-氟-苯基）亚甲基的双环1,2,4-三唑-3（2H）-one和1,3,5-三嗪-2,4（3H）-二酮衍生物已制备]哌啶或4-（4-氟苯甲酰基）哌啶基团并测试了5-HT 2和α1受体拮抗剂的活性。在制备的化合物中，2- [2- [2- [4- [双（4-氟苯基）亚甲基]-哌啶-1-基]乙基] -5,6,7,8-四氢-1,2,4-三唑[ 4,3-a] pyridin-3（2H）-one（7b）具有最有效的5-HT2拮抗剂活性，高于利坦色林（2），而7b在体内未显示出α1拮抗剂活性。当测试阻断5-羟色氨酸诱导的头部抽搐的能力时，中央5-HT 2受体拮抗作用约为2的1/30。化合物21b，3- [2- [4-（4-氟苯甲酰基）哌啶-1-基]乙基] -6,7,8,9-四氢-2H-吡啶基[1,2-a] -1,3， 5-三嗪-2，4（3H）-二酮也显示出有效的5-HT2拮抗剂活性
• TRICYCLIC TRIAZOLE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0536419A1

  公开（公告）日：1993-04-14

  A novel tricyclic triazole derivative represented by general formula (I) and a pharmacologically acceptable salt thereof, useful as an antiinflammatory, antiallergic and anti-PAF drug, and a process for the production thereof. In formula (I), R¹ represents hydrogen, lower alkyl or C₃ to C₅ cycloalkyl; R² and R³ represent each hydrogen, lower alkyl, lower alkoxy or halogen; W represents C = O or CR⁴R⁵ wherein R⁴ and R⁵ represent each hydrogen or lower alkyl; A represents C₁ to C₅ saturated or unsaturated alkylene which may contain a heteroatom; 1 represents 0 to 2; n represents 1 to 3; symbol --¯ represents a single or double bond; Y represents N or C; and Z represents C(B)Ar¹Ar² (wherein B represents hydrogen, hydroxy or methoxy, and Ar¹ and Ar² represent each hydrogen or (un)substituted aryl), CAr¹Ar² (wherein Ar¹ and Ar² are each as defined above), O-CHAr¹Ar² (wherein Ar¹ and Ar² are each as defined above) or a condensed aromatic ring.

  一种由通式(I)代表的新型三环三唑衍生物及其药理学上可接受的盐，可用作抗炎、抗过敏和抗PAF药物，及其生产工艺。在式 (I) 中，R¹ 代表氢、低级烷基或 C₃ 至 C₅ 环烷基；R² 和 R³ 分别代表氢、低级烷基、低级烷氧基或卤素；W 代表 C = O 或 CR⁴R⁵，其中 R⁴ 和 R⁵ 各自代表氢或低级烷基；A 代表 C₁ 至 C₅ 饱和或不饱和亚烷基，其中可包含一个杂原子；1 代表 0 至 2；n 代表 1 至 3；符号--¯代表单键或双键；Y代表N或C；Z代表C(B)Ar¹Ar²（其中B代表氢、羟基或甲氧基，Ar¹和Ar²分别代表氢或（未）取代的芳基）、CAr¹Ar²（其中Ar¹和Ar²分别如上定义）、O-CHAr¹Ar²（其中Ar¹和Ar²分别如上定义）或缩合芳环。
• Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP0401707B1

  公开（公告）日：1994-09-21